{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T02:22:17Z","timestamp":1787710937913,"version":"build-2784847793"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"ZonMw","award":["10140292110006"],"award-info":[{"award-number":["10140292110006"]}]},{"name":"ZonMw","award":["10140292110006"],"award-info":[{"award-number":["10140292110006"]}]},{"name":"ZonMw","award":["10140292110006"],"award-info":[{"award-number":["10140292110006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-026-03716-0","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:54:07Z","timestamp":1781697247000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Design of a randomized controlled trial comparing hybrid care with standard care for people with pulmonary fibrosis"],"prefix":"10.1186","volume":"27","author":[{"given":"Delian E.","family":"Hofman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina C.","family":"Moor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frouke F.","family":"van Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriane D.M.","family":"Vorselaars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Overbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"van Doorn-Hogervorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda A.A.","family":"Moonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"van der Maten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bresser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan W.","family":"Loth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline","family":"Schakenraad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Kerstens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"van der Wal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"de Mul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9my L.M.","family":"Mostard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies S.","family":"Wijsenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"issue":"10","key":"3716_CR1","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMra2005230","volume":"3","author":"M Wijsenbeek","year":"2020","unstructured":"Wijsenbeek M, Cottin V. Spectrum of Fibrotic Lung Diseases. N Engl J Med Sep. 2020;3(10):958\u201368. https:\/\/doi.org\/10.1056\/NEJMra2005230.","journal-title":"N Engl J Med Sep"},{"issue":"5","key":"3716_CR2","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"1","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. Sep 2018;1(5):e44\u201368.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"3716_CR3","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"1","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. May 2022;1(9):e18\u201347.","journal-title":"Am J Respir Crit Care Med"},{"key":"3716_CR4","doi-asserted-by":"crossref","unstructured":"Johannson KA, Vittinghoff E, Morisset J, Lee JS, Balmes JR, Collard HR. Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis. Eur Respir J. 2017;50(1):1602406.","DOI":"10.1183\/13993003.02406-2016"},{"key":"3716_CR5","doi-asserted-by":"crossref","unstructured":"Noth I, Cottin V, Chaudhuri N et al. Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial. Eur Respir J. 2021;58(1):20051518.","DOI":"10.1183\/13993003.01518-2020"},{"issue":"2","key":"3716_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","volume":"8","author":"TM Maher","year":"2020","unstructured":"Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respiratory Med. 2020;8(2):147\u201357. https:\/\/doi.org\/10.1016\/S2213-2600(19)30341-8. 2020\/02\/01\/.","journal-title":"Lancet Respiratory Med"},{"key":"3716_CR7","doi-asserted-by":"publisher","unstructured":"Hofman DE, Moor CC, Mostard RLM et al. Healthcare Professionals\u2019 Perspectives on Implementation of Home Monitoring in Individuals with Pulmonary Fibrosis. ERJ Open Res. 2025:00709\u20132025. https:\/\/doi.org\/10.1183\/23120541.00709-2025","DOI":"10.1183\/23120541.00709-2025"},{"key":"3716_CR8","doi-asserted-by":"crossref","unstructured":"Althobiani M, Alqahtani JS, Hurst JR, Russell AM, Porter J. Telehealth for patients with interstitial lung diseases (ILD): results of an international survey of clinicians. BMJ Open Respir Res. 2021;8(1):e001088.","DOI":"10.1136\/bmjresp-2021-001088"},{"key":"3716_CR9","doi-asserted-by":"crossref","unstructured":"Nakshbandi G, Moor CC, Johannson KA, Maher TM, Kreuter M, Wijsenbeek MS. Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era. ERJ Open Res. 2021;7(3):00405-2021.","DOI":"10.1183\/23120541.00405-2021"},{"issue":"8","key":"3716_CR10","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1164\/rccm.201511-2152OC","volume":"15","author":"AM Russell","year":"2016","unstructured":"Russell AM, Adamali H, Molyneaux PL, et al. Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med Oct. 2016;15(8):989\u201397.","journal-title":"Am J Respir Crit Care Med Oct"},{"issue":"3","key":"3716_CR11","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1513\/AnnalsATS.202103-319RL","volume":"19","author":"SC Carde\u00f1osa","year":"2022","unstructured":"Carde\u00f1osa SC, Palomo M, Francesqui J, et al. Home Oxygen Monitoring in Patients with Interstitial Lung Disease. Ann Am Thorac Soc Mar. 2022;19(3):493\u20137.","journal-title":"Ann Am Thorac Soc Mar"},{"issue":"1","key":"3716_CR12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12890-017-0495-2","volume":"2017\/11\/23","author":"ED Root","year":"2017","unstructured":"Root ED, Graney B, Baird S, et al. Physical activity and activity space in patients with pulmonary fibrosis not prescribed supplemental oxygen. BMC Pulm Med. 2017;2017\/11\/23(1):154. https:\/\/doi.org\/10.1186\/s12890-017-0495-2.","journal-title":"BMC Pulm Med"},{"issue":"3","key":"3716_CR13","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1016\/s2665-9913(24)00236-4","volume":"7","author":"A Velauthapillai","year":"2025","unstructured":"Velauthapillai A, Moor CC, de Vries-Bouwstra JK, Wijsenbeek-Lourens MS, van den Ende CHM, Vonk MC. Detection of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease using home monitoring in the Netherlands (DecreaSSc): a prospective, observational study. doi: 10.1016\/S2665-9913(24)00236-4. Lancet Rheumatol. 2025;7(3):e178\u201386. https:\/\/doi.org\/10.1016\/s2665-9913(24)00236-4.","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"3716_CR14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1164\/rccm.202002-0328OC","volume":"1","author":"CC Moor","year":"2020","unstructured":"Moor CC, Mostard RLM, Grutters JC, et al. Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis. A Randomized Controlled Trial. Am J Respir Crit Care Med. Aug 2020;1(3):393\u2013401. https:\/\/doi.org\/10.1164\/rccm.202002-0328OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"3716_CR15","doi-asserted-by":"publisher","first-page":"d4163","DOI":"10.1136\/bmj.d4163","volume":"343","author":"M Huber","year":"2011","unstructured":"Huber M, Knottnerus JA, Green L, et al. How should we define health? BMJ. 2011;343:d4163. https:\/\/doi.org\/10.1136\/bmj.d4163.","journal-title":"BMJ"},{"key":"3716_CR16","doi-asserted-by":"publisher","unstructured":"Barlow J, Wright C, Sheasby J, Turner A, Hainsworth J. Self-management approaches for people with chronic conditions: a review. Patient Education and Counseling. 2002\/10\/01\/ 2002;48(2):177\u2013187. https:\/\/doi.org\/10.1016\/S0738-3991(02)00032-0","DOI":"10.1016\/S0738-3991(02)00032-0"},{"issue":"9666","key":"3716_CR17","first-page":"781","volume":"7","author":"What is health?","year":"2009","unstructured":"What is health?. The ability to adapt. Lancet Mar. 2009;7(9666):781.","journal-title":"Lancet Mar"},{"issue":"1","key":"3716_CR18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000518216","volume":"101","author":"AEM Bloem","year":"2022","unstructured":"Bloem AEM, Mostard RLM, Stoot N, et al. Patient Activation for Self-Management in Patients with Idiopathic Pulmonary Fibrosis or Sarcoidosis. Respiration. 2022;101(1):76\u201383.","journal-title":"Respiration"},{"issue":"4 Pt 1","key":"3716_CR19","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1111\/j.1475-6773.2004.00269.x","volume":"39","author":"JH Hibbard","year":"2004","unstructured":"Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res Aug. 2004;39(4 Pt 1):1005\u201326.","journal-title":"Health Serv Res Aug"},{"issue":"1","key":"3716_CR20","doi-asserted-by":"publisher","first-page":"e001167","DOI":"10.1136\/bmjresp-2021-001167","volume":"9","author":"JS Jeffrey","year":"2022","unstructured":"Jeffrey JS, Donald MB, Klaus R, Heiko M, Michael B, Yoshikazu I. Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases. BMJ Open Respiratory Res. 2022;9(1):e001167. https:\/\/doi.org\/10.1136\/bmjresp-2021-001167.","journal-title":"BMJ Open Respiratory Res"},{"key":"3716_CR21","doi-asserted-by":"crossref","unstructured":"Swigris J, Cutts K, Male N, Baldwin M, Rohr KB, Bushnell DM. The Living with Pulmonary Fibrosis questionnaire in progressive fibrosing interstitial lung disease. ERJ Open Res. 2021;7(2):00145-2020.","DOI":"10.1183\/23120541.00145-2020"},{"issue":"9","key":"3716_CR22","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.rmed.2013.06.009","volume":"107","author":"AS Patel","year":"2013","unstructured":"Patel AS, Siegert RJ, Keir GJ, et al. The minimal important difference of the King\u2019s Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease. Respir Med. 2013;107(9):1438\u201343. https:\/\/doi.org\/10.1016\/j.rmed.2013.06.009. 2013\/09\/01\/.","journal-title":"Respir Med"},{"issue":"9","key":"3716_CR23","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1136\/thoraxjnl-2012-201581","volume":"67","author":"AS Patel","year":"2012","unstructured":"Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the King\u2019s Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax Sep. 2012;67(9):804\u201310.","journal-title":"Thorax Sep"},{"key":"3716_CR24","doi-asserted-by":"publisher","unstructured":"Prior TS, Hoyer N, Hilberg O, et al. Responsiveness and minimal clinically important difference of SGRQ-I and K-BILD in idiopathic pulmonary fibrosis. Respir Res. 2020;21:91. https:\/\/doi.org\/10.1186\/s12931-020-01359-3.","DOI":"10.1186\/s12931-020-01359-3"},{"key":"3716_CR25","doi-asserted-by":"publisher","unstructured":"Nolan CM, Birring SS, Maddocks M, et al. King's Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important difference. Eur Respir J. 2019;54:1900281. https:\/\/doi.org\/10.1183\/13993003.00281-2019.","DOI":"10.1183\/13993003.00281-2019"},{"key":"3716_CR26","doi-asserted-by":"crossref","unstructured":"Tsai APY, Hur SA, Wong A, Safavi M, Assayag D, Johannson KA, Morisset J, Fell C, Fisher JH, Manganas H, Shapera S, Cox G, Gershon AS, Hambly N, Khalil N, To T, Wilcox PG, Halayko A, Kolb MR, Ryerson CJ. Minimum importantdifference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease. Thorax. 2021;76(1):37\u201343.","DOI":"10.1136\/thoraxjnl-2020-214944"},{"issue":"8","key":"3716_CR27","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/qjmed\/hcy102","volume":"111","author":"H Yates","year":"2018","unstructured":"Yates H, Adamali HI, Maskell N, Barratt S, Sharp C. Visual analogue scales for interstitial lung disease: a prospective validation study. QJM: Int J Med. 2018;111(8):531\u20139. https:\/\/doi.org\/10.1093\/qjmed\/hcy102.","journal-title":"QJM: Int J Med"},{"key":"3716_CR28","doi-asserted-by":"crossref","unstructured":"Moor CC, Mostard RLM, Grutters JC, Bresser P, Wijsenbeek MS. The use of online visual analogue scales in idiopathic pulmonary fibrosis. Eur Respir J. 2022;59(1):2101531.","DOI":"10.1183\/13993003.01531-2021"},{"issue":"suppl 60","key":"3716_CR29","doi-asserted-by":"publisher","first-page":"PA793","DOI":"10.1183\/13993003.congress-2016.PA793","volume":"48","author":"MS Wijsenbeek","year":"2016","unstructured":"Wijsenbeek MS, Kimman ML, Rotteveel A, et al. The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF). Eur Respir J. 2016;48(suppl 60):PA793. https:\/\/doi.org\/10.1183\/13993003.congress-2016.PA793.","journal-title":"Eur Respir J"},{"issue":"1","key":"3716_CR30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40271-018-0340-6","volume":"12","author":"ML Kimman","year":"2019","unstructured":"Kimman ML, Wijsenbeek MS, van Kuijk SMJ, et al. Validity of the Patient Experiences and Satisfaction with Medications (PESaM) Questionnaire. Patient Feb. 2019;12(1):149\u201362.","journal-title":"Patient Feb"},{"issue":"1","key":"3716_CR31","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12931-020-01458-1","volume":"23","author":"CC Moor","year":"2020","unstructured":"Moor CC, Mostard RLM, Grutters JC, et al. Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study. Respir Res Jul. 2020;23(1):196.","journal-title":"Respir Res Jul"},{"key":"3716_CR32","unstructured":"\u00a0iMTA Productivity and Health Research Group. Manual iMTA Medical CostQuestionnaire (iMCQ). Rotterdam: iMTA, Erasmus University Rotterdam, 2018. Available in Dutch and English."},{"key":"3716_CR33","doi-asserted-by":"crossref","unstructured":"Adapted iMCQ & iPCQ' Bouwmans C, Krol M, Severens H, Koopmanschap M, Brouwer W,Hakkaart-van Roijen L. The iMTA Productivity Cost Questionnaire: A Standardized Instrument for Measuring and Valuing Health-RelatedProductivity Losses. Value Health. 2015 Sep;18(6):753-8.","DOI":"10.1016\/j.jval.2015.05.009"},{"issue":"8","key":"3716_CR34","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","volume":"15","author":"BL Graham","year":"2019","unstructured":"Graham BL, Steenbruggen I, Miller MR, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med Oct. 2019;15(8):e70\u201388.","journal-title":"Am J Respir Crit Care Med Oct"},{"key":"3716_CR35","doi-asserted-by":"crossref","unstructured":"Topole E, Biondaro S, Montagna I et al. Artificial intelligence based software facilitates spirometry quality control in asthma and COPD clinical trials. ERJ Open Res. 2023;9(1):00292-2022.","DOI":"10.1183\/23120541.00292-2022"},{"key":"3716_CR36","unstructured":"Ageing. and health. World Health Organization. 2025. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/ageing-and-health."},{"key":"3716_CR37","doi-asserted-by":"publisher","unstructured":"Walensky Rochelle P, McCann Nicole C. Challenges to the Future of a Robust Physician Workforce in the United States. doi: 10.1056\/NEJMsr2412784. N Engl J Med. 2025\/01\/15 2025;392(3):286\u201395. https:\/\/doi.org\/10.1056\/NEJMsr2412784","DOI":"10.1056\/NEJMsr2412784"},{"issue":"1","key":"3716_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41746-024-01427-8","volume":"2025\/01\/08","author":"A-JS Jansen","year":"2025","unstructured":"Jansen A-JS, Peters GM, Kooij L, Doggen CJM, van Harten WH. Device based monitoring in digital care and its impact on hospital service use. npj Digit Med. 2025;2025\/01\/08(1):16. https:\/\/doi.org\/10.1038\/s41746-024-01427-8.","journal-title":"npj Digit Med"},{"issue":"4","key":"3716_CR39","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1097\/AOG.0000000000005327","volume":"1","author":"BJ Arkerson","year":"2023","unstructured":"Arkerson BJ, Finneran MM, Harris SR, et al. Remote Monitoring Compared With In-Office Surveillance of Blood Pressure in Patients With Pregnancy-Related Hypertension: A Randomized Controlled Trial. Obstet Gynecol Oct. 2023;1(4):855\u201361.","journal-title":"Obstet Gynecol Oct"},{"issue":"1","key":"3716_CR40","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12877-018-0911-3","volume":"21","author":"A Lopez-Villegas","year":"2018","unstructured":"Lopez-Villegas A, Catalan-Matamoros D, Lopez-Liria R, Enebakk T, Thunhaug H, Lappeg\u00e5rd KT. Health-related quality of life on tele-monitoring for users with pacemakers 6 months after implant: the NORDLAND study, a randomized trial. BMC Geriatr. Sep 2018;21(1):223.","journal-title":"BMC Geriatr"},{"key":"3716_CR41","doi-asserted-by":"publisher","first-page":"e3874","DOI":"10.1136\/bmj.e3874","volume":"344","author":"A Steventon","year":"2012","unstructured":"Steventon A, Bardsley M, Billings J, et al. Effect of telehealth on use of secondary care and mortality: findings from the Whole System Demonstrator cluster randomised trial. Bmj Jun 21. 2012;344:e3874.","journal-title":"Bmj Jun 21"},{"issue":"8","key":"3716_CR42","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1177\/1357633X14555644","volume":"20","author":"A Villani","year":"2014","unstructured":"Villani A, Malfatto G, Compare A, et al. Clinical and psychological telemonitoring and telecare of high risk heart failure patients. J Telemed Telecare Dec. 2014;20(8):468\u201375.","journal-title":"J Telemed Telecare Dec"},{"issue":"4","key":"3716_CR43","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.pec.2021.07.005","volume":"105","author":"JYT Lee","year":"2022","unstructured":"Lee JYT, Tikellis G, Glaspole I, Khor YH, Symons K, Holland AE. Self-management for pulmonary fibrosis: Insights from people living with the disease and healthcare professionals. Patient Educ Couns. 2022;105(4):956\u201364. https:\/\/doi.org\/10.1016\/j.pec.2021.07.005. 2022\/04\/01\/.","journal-title":"Patient Educ Couns"},{"key":"3716_CR44","doi-asserted-by":"publisher","unstructured":"Riegler TF, Marcin T, Wirz M, et al. Living with pulmonary fibrosis: how affected people experience disease-related information, health services and self-management strategies. BMJ Open Respir Res Nov. 2025;28(1). https:\/\/doi.org\/10.1136\/bmjresp-2025-003303.","DOI":"10.1136\/bmjresp-2025-003303"},{"key":"3716_CR45","doi-asserted-by":"publisher","unstructured":"What Is Patient-Centered. Care? doi: 10.1056\/CAT.17.0559. Catalyst Carryover. 3(1)https:\/\/doi.org\/10.1056\/cat.17.0559","DOI":"10.1056\/cat.17.0559"},{"key":"3716_CR46","doi-asserted-by":"publisher","unstructured":"Rosalia RA, Wahba K, Milevska-Kostova N. How digital transformation can help achieve value-based healthcare: Balkans as a case in point. doi: 10.1016\/j.lanepe.2021.100100. Lancet Reg Health \u2013 Europe. 2021;4. https:\/\/doi.org\/10.1016\/j.lanepe.2021.100100.","DOI":"10.1016\/j.lanepe.2021.100100"},{"key":"3716_CR47","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.puhe.2022.06.021","volume":"210","author":"G Anderson","year":"2022","unstructured":"Anderson G, Rega ML, Casasanta D, Graffigna G, Damiani G, Barello S. The association between patient activation and healthcare resources utilization: a systematic review and meta-analysis. Public Health Sep. 2022;210:134\u201341.","journal-title":"Public Health Sep"},{"issue":"2","key":"3716_CR48","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1377\/hlthaff.2012.1061","volume":"32","author":"JH Hibbard","year":"2013","unstructured":"Hibbard JH, Greene J. What the evidence shows about patient activation: better health outcomes and care experiences; fewer data on costs. Health Aff (Millwood) Feb. 2013;32(2):207\u201314.","journal-title":"Health Aff (Millwood) Feb"},{"key":"3716_CR49","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1183\/23120541.01234-2024","volume":"01234","author":"G Nakshbandi","year":"2025","unstructured":"Nakshbandi G, Moor K, Magr\u00ec T, et al. Online home spirometry in national pulmonary fibrosis care: insights from daily practice. ERJ Open Res. 2025;01234:2024. https:\/\/doi.org\/10.1183\/23120541.01234-2024.","journal-title":"ERJ Open Res"},{"key":"3716_CR50","doi-asserted-by":"publisher","unstructured":"Gillett G, Shah RJ, DeDent AM, Farrand E. Remote Patient Monitoring for Managing Interstitial Lung Disease: A Mixed-Methods Process Evaluation. doi: 10.1016\/j.chpulm.2024.100122. CHEST Pulmonary. 2025;3(1). https:\/\/doi.org\/10.1016\/j.chpulm.2024.100122.","DOI":"10.1016\/j.chpulm.2024.100122"},{"key":"3716_CR51","doi-asserted-by":"publisher","unstructured":"Nakshbandi G, Moor K, Vorselaars AD, Wijsenbeek MS. Evaluation of home monitoring for patients with interstitial lung disease during the COVID-19 pandemic. Eur Respir J. 60(suppl 66):681. https:\/\/doi.org\/10.1183\/13993003.congress-2022.681","DOI":"10.1183\/13993003.congress-2022.681"},{"issue":"3","key":"3716_CR52","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1001\/jamainternmed.2020.5928","volume":"181","author":"SY Patel","year":"2021","unstructured":"Patel SY, Mehrotra A, Huskamp HA, Uscher-Pines L, Ganguli I, Barnett ML. Trends in Outpatient Care Delivery and Telemedicine During the COVID-19 Pandemic in the US. JAMA Intern Med. 2021;181(3):388\u201391. https:\/\/doi.org\/10.1001\/jamainternmed.2020.5928.","journal-title":"JAMA Intern Med"},{"issue":"23","key":"3716_CR53","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1056\/NEJMp2005835","volume":"382","author":"K Sirina","year":"2020","unstructured":"Sirina K, Andrea J, Kevin S. Covid-19 and Health Care\u2019s Digital Revolution. N Engl J Med. 2020;382(23):e82. https:\/\/doi.org\/10.1056\/NEJMp2005835.","journal-title":"N Engl J Med"},{"key":"3716_CR54","unstructured":"Equity within digital health technology within the WHO European Region : a scoping review. World Health Organization; 2022 https:\/\/iris.who.int\/bitstream\/handle\/10665\/365326\/WHO-EURO-2022-6810-46576-67595-eng.pdf?sequence=1"},{"key":"3716_CR55","unstructured":"Khor YH, Poberezhets V, Buhr RG et al. Assessment of Home-based Monitoring in Adults with Chronic Lung Disease. An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med. 25 2024."},{"issue":"2","key":"3716_CR56","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10488-010-0319-7","volume":"38","author":"E Proctor","year":"2011","unstructured":"Proctor E, Silmere H, Raghavan R, et al. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Adm Policy Ment Health Mar. 2011;38(2):65\u201376. https:\/\/doi.org\/10.1007\/s10488-010-0319-7.","journal-title":"Adm Policy Ment Health Mar"},{"issue":"1","key":"3716_CR57","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11136-023-03505-y","volume":"33","author":"E Unni","year":"2024","unstructured":"Unni E, Coles T, Lavallee DC, Freel J, Roberts N, Absolom K. Patient adherence to patient-reported outcome measure (PROM) completion in clinical care: current understanding and future recommendations. Qual Life Res Jan. 2024;33(1):281\u201390.","journal-title":"Qual Life Res Jan"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03716-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03716-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03716-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T02:08:34Z","timestamp":1787710114000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-026-03716-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3716"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03716-0","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study will be performed according to the principles of the Declaration of Helsinki and in accordance with the Medical Research Involving Human Subjects Act. This study is exempt from ethics, as approved by the IRB Medical Ethics Committee (METC) of Erasmus Medical Center, Rotterdam, the Netherlands, with the protocol reference number MEC-2024-0045, date of approval: 23-05-2024. Approval from the Medical Ethics Committee of all participating sites is also obtained. Written informed consent will be obtained from all participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DH: Support for the present study from ZonMw \/ the Netherlands Organisation for Health Research and Development paid to institution. CM: Support for the present study from ZonMw \/ the Netherlands Organisation for Health Research and Development, grants outside the submitted work from Boehringer-Ingelheim and Astra-Zeneca-Daiichi Sankyo paid to institution, payments for presentations\/lectures from Boehringer-Ingelheim and GSK paid to institution, support for travel from Boehringer-Ingelheim paid to institution, and leadership roles with the ERS Early Career Member Committee, Early Career Member Representative of the ILD Assembly, Professional Advisory Committee European Lung Foundation, and Advocacy Council ERS. FvB: No disclosures to report. AV: No disclosures to report. MO: No disclosures to report. KvD: No disclosures to report. LM: No disclosures to report. JvdM: No disclosures to report. PB: No disclosures to report. DL: Support for travel from Boehringer-Ingelheim and board member of the section ILD Dutch Society for Chest physicians (NVALT). ES: No disclosures to report. RK: No disclosures to report. PvdW: No disclosures to report. MdM: No disclosures to report. RM: Grants outside the submitted work from the Dutch pulmonary fibrosis patient society and Boehringer-Ingelheim paid to institution, payment or honoraria for presentations from GSK, Boehringer-Ingelheim, Astra-Zeneca, and Johnson & Johnson, participation on a data safety monitoring board from Boehringer-Ingelheim, and member of the executive committee WASOG up to 2024, Dutch asbestosis expert panel, board member section ILD Dutch Society for Chest physicians (NVALT) up to 2023, advisory board for the Dutch pulmonary fibrosis patient society, and President Regional Central Educational Committee OORZON. MW: Support for the present study from ZonMw \/ the Netherlands Organisation for Health Research and Development paid to institution, grants outside the submitted work from Astra-Zeneca-Daiichi Sankyo, Boehringer-Ingelheim, Erasmus MC, Hoffmann-La Roche, Sarcoidosis.nl, The Dutch Lung Foundation, The Dutch Pulmonary Fibrosis Patients Association, The Netherlands Organization for Health Research and Development, The Thorax Foundation paid to institution, consulting fees from Astra-Zeneca-Daiichi Sankyo, Avalyn Pharma, Boehringer-Ingelheim, Bristol-Myers Squibb, CSL Behring, Galapagos, Galecto, GlaxoSmithKline, Hoffmann-La Roche, Horizon Therapeutics, Kinevant Sciences, Molecure, NeRRe Therapeutics, Novartis, PureTech Health, Trevi, and Vicore outside submitted work paid to institution, payment or honoraria for presentations from Avalyn Pharma, Boehringer-Ingelheim, Sanofi, CSL Behring, and Novartis, support for travel from Boehringer-Ingelheim, GSK, and Hoffmann-La Roche, and leadership roles as secretary of ILD assembly for European Respiratory Society, Board member of the Netherlands Respiratory Society, Scientific advisory board of European idiopathic pulmonary fibrosis and related disorders federation, chair of educational committee of European Reference Network for Rare Lung Diseases, and advisory board of Dutch lung fibrosis and sarcoidosis patient associations.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"330"}}